Status: Not yet recruiting
A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL
Comparison of MODIFIED progression-free survival (Modified-PFS) in high-dose rituximab (500mg/m²) plus CHOP versus standard-dose rituximab plus CHOP in previously untreated (TN) stage III-IV male DLBCL patients
Participants needed: 428
Trial details
Phase: Phase 3Age: 18-75Biological sex: MaleType: InterventionalSponsor: Xia YiUpdated: Aug 27, 2024
Eligibility criteria
age <75y, male patients [+8]
Subjects assessed by the investigator to be intolerant to the R-CHOP regimen and... [+15]